E
Editas Medicine, Inc. (EDIT)
2.23
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
2.23
0.00 (0.00%)
Editas Medicine, Inc., klinik bosqichdagi gen tahrirlash kompaniyasi, bir qator jiddiy kasalliklarni davolash uchun transformatsion genetik dori vositalarini ishlab chiqishga qaratilgan. Kompaniya CRISPR texnologiyasiga asoslangan o'ziga xos gen tahrirlash platformasini ishlab chiqadi. Uning asosiy dasturi EDIT-401 bo'lib, bu giperlipidemiya kasalligini davolash uchun LDL retseptorining yuqori ekspressiyasi orqali LDL xolesterinini kamaytirishga mo'ljallangan bir martalik terapiyadir. Kompaniya, shuningdek, O'roqsimon hujayrali anemiya va transfüzyonga bog'liq bo'lgan beta-talassemiyani davolash uchun terapiyalarni ishlab chiqadi; va boshqa hujayralar va to'qimalarga mo'ljallangan in vivo gen tahrirlash dori vositalari. U Juno Therapeutics, Inc. bilan qattiq va suyuq o'smalar hamda autoimmün kasalliklarni davolash uchun alfa-beta T-hujayrali eksperimental dori vositalarini ishlab chiqish bo'yicha tadqiqot hamkorligiga ega. Kompaniya ilgari Gengine, Inc. nomi bilan tanilgan va 2013-yil noyabr oyida Editas Medicine, Inc. nomini o'zgartirgan. Editas Medicine, Inc. 2013-yilda ro'yxatga olingan va Kembrij, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Gilmore O'Neill M.D. | President, CEO & Director |
| Dr. Linda C. Burkly Ph.D. | Executive VP & Chief Scientific Officer |
| Mr. Damien Grierson J.D. | Senior VP, General Counsel & Corporate Secretary |
| Mr. Frank Panaccio | Senior VP & Chief Business Officer |
| Mr. Gregory Whitehead | Executive VP and Chief Technical & Quality Officer |
| Ms. Amy Parison | Senior VP & CFO |
| Ms. Brieana Buckley | Senior Vice President of Development and Program Leadership |
| Ms. Cristi Barnett | Senior VP of Corporate Communications & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-09 | 10-K | edit-20251231.htm |
| 2025-11-10 | 10-Q | edit-20250930.htm |
| 2025-10-09 | 8-K | edit-20251009.htm |
| 2025-09-02 | 8-K | edit-20250902.htm |
| 2025-08-12 | 10-Q | edit-20250630.htm |
| 2025-06-12 | 8-K | edit-20250612.htm |
| 2025-06-02 | 8-K | edit-20250529.htm |
| 2025-05-14 | 8-K | edit-20250514.htm |
| 2025-05-13 | 8-K | edit-20250513.htm |
| 2025-05-12 | 10-Q | edit-20250331.htm |